IBDEI287 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37750,1,4,0)
 ;;=4^M22.41
 ;;^UTILITY(U,$J,358.3,37750,2)
 ;;=^5011186
 ;;^UTILITY(U,$J,358.3,37751,0)
 ;;=M22.42^^140^1801^1
 ;;^UTILITY(U,$J,358.3,37751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37751,1,3,0)
 ;;=3^Chondromalacia patellae, lft knee
 ;;^UTILITY(U,$J,358.3,37751,1,4,0)
 ;;=4^M22.42
 ;;^UTILITY(U,$J,358.3,37751,2)
 ;;=^5011187
 ;;^UTILITY(U,$J,358.3,37752,0)
 ;;=M23.91^^140^1801^4
 ;;^UTILITY(U,$J,358.3,37752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37752,1,3,0)
 ;;=3^Intrnl derangement of rt knee, unspec
 ;;^UTILITY(U,$J,358.3,37752,1,4,0)
 ;;=4^M23.91
 ;;^UTILITY(U,$J,358.3,37752,2)
 ;;=^5133806
 ;;^UTILITY(U,$J,358.3,37753,0)
 ;;=M23.92^^140^1801^3
 ;;^UTILITY(U,$J,358.3,37753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37753,1,3,0)
 ;;=3^Intrnl derangement of lft knee, unspec
 ;;^UTILITY(U,$J,358.3,37753,1,4,0)
 ;;=4^M23.92
 ;;^UTILITY(U,$J,358.3,37753,2)
 ;;=^5133807
 ;;^UTILITY(U,$J,358.3,37754,0)
 ;;=M02.00^^140^1802^1
 ;;^UTILITY(U,$J,358.3,37754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37754,1,3,0)
 ;;=3^Arthropathy following intest bypass, unspec site
 ;;^UTILITY(U,$J,358.3,37754,1,4,0)
 ;;=4^M02.00
 ;;^UTILITY(U,$J,358.3,37754,2)
 ;;=^5009718
 ;;^UTILITY(U,$J,358.3,37755,0)
 ;;=L52.^^140^1802^2
 ;;^UTILITY(U,$J,358.3,37755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37755,1,3,0)
 ;;=3^Erythema nodosum
 ;;^UTILITY(U,$J,358.3,37755,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,37755,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,37756,0)
 ;;=L40.59^^140^1802^3
 ;;^UTILITY(U,$J,358.3,37756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37756,1,3,0)
 ;;=3^Psoriatic arthropathy, oth
 ;;^UTILITY(U,$J,358.3,37756,1,4,0)
 ;;=4^L40.59
 ;;^UTILITY(U,$J,358.3,37756,2)
 ;;=^5009170
 ;;^UTILITY(U,$J,358.3,37757,0)
 ;;=M02.30^^140^1802^4
 ;;^UTILITY(U,$J,358.3,37757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37757,1,3,0)
 ;;=3^Reactive Arthritis,Unspec Site
 ;;^UTILITY(U,$J,358.3,37757,1,4,0)
 ;;=4^M02.30
 ;;^UTILITY(U,$J,358.3,37757,2)
 ;;=^5009790
 ;;^UTILITY(U,$J,358.3,37758,0)
 ;;=M94.1^^140^1802^5
 ;;^UTILITY(U,$J,358.3,37758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37758,1,3,0)
 ;;=3^Relapsing polychondritis
 ;;^UTILITY(U,$J,358.3,37758,1,4,0)
 ;;=4^M94.1
 ;;^UTILITY(U,$J,358.3,37758,2)
 ;;=^5015328
 ;;^UTILITY(U,$J,358.3,37759,0)
 ;;=Z79.52^^140^1803^4
 ;;^UTILITY(U,$J,358.3,37759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37759,1,3,0)
 ;;=3^Long Term (Current) Use of Systemic Steroids
 ;;^UTILITY(U,$J,358.3,37759,1,4,0)
 ;;=4^Z79.52
 ;;^UTILITY(U,$J,358.3,37759,2)
 ;;=^5063336
 ;;^UTILITY(U,$J,358.3,37760,0)
 ;;=Z79.899^^140^1803^3
 ;;^UTILITY(U,$J,358.3,37760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37760,1,3,0)
 ;;=3^Long Term (Current) Drug Therapy,Other
 ;;^UTILITY(U,$J,358.3,37760,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,37760,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,37761,0)
 ;;=Z82.69^^140^1803^2
 ;;^UTILITY(U,$J,358.3,37761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37761,1,3,0)
 ;;=3^Family Hx of MS System/Connective Tissue Diseases,Other
 ;;^UTILITY(U,$J,358.3,37761,1,4,0)
 ;;=4^Z82.69
 ;;^UTILITY(U,$J,358.3,37761,2)
 ;;=^5063373
 ;;^UTILITY(U,$J,358.3,37762,0)
 ;;=Z82.61^^140^1803^1
 ;;^UTILITY(U,$J,358.3,37762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37762,1,3,0)
 ;;=3^Family Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,37762,1,4,0)
 ;;=4^Z82.61
 ;;^UTILITY(U,$J,358.3,37762,2)
 ;;=^5063371
 ;;^UTILITY(U,$J,358.3,37763,0)
 ;;=94640^^141^1804^1^^^^1
 ;;^UTILITY(U,$J,358.3,37763,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,37763,1,1,0)
 ;;=1^94640
